Regeneron Pharmaceuticals (REGN) Net Cash Flow (2009 - 2026)

Regeneron Pharmaceuticals' Net Cash Flow history runs 18 years deep, the most recent figure standing at -$504.3 million for Q2 2026.

• In Q2 2026, Net Cash Flow rose 53.21% year-over-year to -$504.3 million; the TTM figure through Jun 2026 stood at $452.3 million (up 424.1% YoY), while the FY2025 annual figure was $634.4 million, up 355.7% from the prior year.
• Net Cash Flow for Q2 2026 stood at -$504.3 million, down from -$152.2 million in the prior quarter.
• The five-year high for Net Cash Flow was $809.4 million in Q1 2023, with the low at -$2.0 billion in Q2 2023.
• The 5-year median for Net Cash Flow is $89.5 million (2022), against an average of -$23.9 million.
• The sharpest annual moves came in 2023 and 2025: Net Cash Flow slumped 4105.47% in 2023, then soared 573.25% in 2025.
• Regeneron Pharmaceuticals' Net Cash Flow stood at -$385.4 million in 2022, then surged by 249.82% to $577.4 million in 2023, then decreased by 17.23% to $477.9 million in 2024, then grew by 27.83% to $610.9 million in 2025, then plunged by 182.55% to -$504.3 million in 2026.
• Business Quant data shows REGN's Net Cash Flow at -$504.3 million in Q2 2026, -$152.2 million in Q1 2026, and $610.9 million in Q4 2025.